Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment
Hazem Choukaife,Salma Seyam,Batoul Alallam,Abd Almonem Doolaanea,Mulham Alfatama
DOI: https://doi.org/10.2147/IJN.S375229
IF: 7.033
2022-09-07
International Journal of Nanomedicine
Abstract:Hazem Choukaife, 1 Salma Seyam, 1 Batoul Alallam, 2 Abd Almonem Doolaanea, 3 Mulham Alfatama 1 1 Faculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, Terengganu, 22200, Malaysia; 2 Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Penang, 13200, Malaysia; 3 Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, 25200, Malaysia Correspondence: Mulham Alfatama, Faculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, Terengganu, 22200, Malaysia, Tel +60 142255604, Email ; As per the WHO, colorectal cancer (CRC) caused around 935,173 deaths worldwide in 2020 in both sexes and at all ages. The available anticancer therapies including chemotherapy, radiotherapy and anticancer drugs are all associated with limited therapeutic efficacy, adverse effects and low chances. This has urged to emerge several novel therapeutic agents as potential therapies for CRC including synthetic and natural materials. Orally administrable and targeted drug delivery systems are attractive strategies for CRC therapy as they minimize the side effects, enhance the efficacy of anticancer drugs. Nevertheless, oral drug delivery till today faces several challenges like poor drug solubility, stability, and permeability. Various oral nano-based approaches and targeted drug delivery systems have been developed recently, as a result of the ability of nanoparticles to control the release of the encapsulant, drug targeting and reduce the number of dosages administered. The unique physicochemical properties of chitosan polymer assist to overcome oral drug delivery barriers and target the colon tumour cells. Chitosan-based nanocarriers offered additional improvements by enhancing the stability, targeting and bioavailability of several anti-colorectal cancer agents. Modified chitosan derivatives also facilitated CRC targeting through strengthening the protection of encapsulant against acidic and enzyme degradation of gastrointestinal track (GIT). This review aims to provide an overview of CRC pathology, therapy and the barriers against oral drug delivery. It also emphasizes the role of nanotechnology in oral drug targeted delivery system and the growing interest towards chitosan and its derivatives. The present review summarizes the relevant works to date that have studied the potential applications of chitosan-based nanocarrier towards CRC treatment. Keywords: chitosan, colorectal cancer, nanocarriers, oral delivery, drug targeting, nanotechnology Colorectal cancer (CRC) is the third most prevailing cancer worldwide. In 2020, CRC caused 506,449 deaths in Asia, 244,824 in Europe, 63,987 in North America and 69,435 in Latin America and the Caribbean. 1 The morbidity is expected to increase up to 1.1 million worldwide by 2030. 2 CRC is usually seen in patients under the age of 50 and it is associated with dietary characteristics and eating habits that contribute to bacterial dysbiosis in the gastrointestinal tract (GIT) and colon cancer. 3 CRC is a type of malignancy that affects the large intestine and rectum regions. 4 It is caused by the deactivation of the p53 pathway or adenomatous polyposis coli gene, the accumulation of mutations such as in K-ras, the transforming growth factor-beta pathway and the genesis of small polyps. The American Joint Committee on Cancer divided CRC into five phases with different treatment strategies for each stage. 5 Stage 0, the presence of abnormal colon cells or polyps on the mucosa, is completely curable with a surgical resection when found early enough. Similarly, surgical excision is the conventional treatment for stages I–II in most cases but with a 5-year survival rate of 37–74%. However, the survival rate drops to 6% in advanced stages of CRC 6 and adjuvant pharmaceutical therapies such as chemotherapy are usually recommended following surgical resection. 7 In stages III–IV, adjuvant chemotherapy like oxaliplatin, 5-fluorouracil, cisplatin, doxorubicin and other emerging medicines are used. However, the administration of these medicines, has been linked to adverse effects, such as vomiting, hair loss and nausea and not demonstrated the expected efficacy. 8 Variety of drawbacks also associated with anticancer drugs, such as hydrophobicity, low water solubility, inadequate biodistribution, and susceptibility to multiple drug resistance. 9 This has urged the need for innovative approaches to enhance the physicochemical and pharmacodynamic properties of standard chemotherapeutics, or achieve target-specific delivery to optimise treatment effectiveness while reducing off-target side effects. 10 Nanoparticle -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology